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Purpose: To evaluate the effects of an anti-rat vascular endothelial growth factor antibody (ARVA) and bevacizumab
(Avastin) on rat retinal Müller glial cells (RMGCs) in vivo and in vitro.
Methods: Rat RMGCs were identified and cultivated, and were then treated with bevacizumab (0.1, 0.25, and 1 mg/ml),
ARVA (0.1, 0.5, and 1 µg/ml), or 1 mg/ml of rat immunoglobulin G (IgG) for 12, 24, 48, and 72 h. The numbers of viable
RMGCs were determined using a trypan blue dye exclusion assay and a methyl thiazolyl tetrazolium colorimetric assay.
In the in vivo study, the rats received intravitreal injections of 5 µl bevacizumab (3.75 mg/ml), ARVA (15 µg/ml), and
rat IgG (1 mg/ml). The electroretinogram was recorded. Seven days after the injections, histopathologic changes and glial
fibrillary acidic protein expression of RMGCs in the retina were analyzed by immunohistochemistry with hematoxylin-
eosin and fluorescent staining.
Results: After exposure to bevacizumab at various concentrations for various periods of time, the stained cell numbers
and optical density values of mitochondrial dehydrogenase activity of RMGCs had no significant differences (p>0.05)
from those of the control group and IgG medium. In the stained cells, ARVA demonstrated a dose-dependent increase.
Compared with those treated for 12 and 24 h, the increase of stained cells treated with 0.5 and 1 µg/ml ARVA at 48 and
72 h was very significant (p<0.01). The optical densities of RMGCs exposed to 0.5 and 1 µg/ml of ARVA at 48 and 72
h were significantly lower than cells exposed to a fresh culture medium (p<0.01). The histology of both treated and control
eyes after intravitreal injection was similar and showed no anatomic signs of toxicity. There were no obvious glial fibrillary
acidic protein upregulations of RMGCs in all groups. The scotopic electroretinogram responses to flashes of light in the
control and treated eyes had similar b-wave amplitudes.
Conclusions: Intravitreal bevacizumab and ARVA had no short-term, direct retinal toxicity in rats. Bevacizumab exerts
no inhibition on rat RMGCs, while ARVA at higher doses (over 0.5 µg/ml) may be harmful to the growth of RMGCs.
Neovascular eye diseases including diabetic retinopathy
(DR)  and  age-related  macular  degeneration  (AMD)  have
become leading causes for substantial and irreversible vision
loss among the populations of industrialized nations [1-3].
Numerous  studies  have  demonstrated  that  vascular
endothelial  growth  factor  (VEGF)  is  a  key  cytokine
responsible for the formation of retinal angiogenesis in DR
and choroidal neovascularization (CNV) in AMD [2,4-6].
Recent advances in understanding the pathogenesis leads to
novel efficacious pharmaceutical treatment of neovascular
diseases, which aims at specific aspects of angiogenesis and
anti-VEGF agents [2,7]; Pegaptanib and Ranibizumab were
approved for treating neovascular AMD by the Food and Drug
Administration  and  the  European  Medicines  Agency  [8].
Bevacizumab  is  a  full  length  recombinant,  humanized
antibody with a molecular weight of 149-kDa, binding to all
isoforms  of  VEGF  and  interfering  with  its  binding  to
receptors, thus inhibiting its signal pathway [9]. Although
bevacizumab is not formally approved for neovascular eye
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disease  treatment,  a  few  multi-center  studies  have
demonstrated that intravitreal injections of bevacizumab have
a beneficial effect on neovascular AMD and DR, improving
visual acuity and reducing retinal edema [10,11].
Previous studies have evaluated the safety of intravitreal
anti-VEGF  agent  injections  in  patients  and  animals  using
physiologic  testing  and  histopathologic  analysis  [12,13].
Some groups reported that bevacizumab showed no retinal
toxicity in rats [14,15]. However, Fuh et al. pointed out that
bevacizumab is human-specific and does not react with rat
VEGF  because  of  an  amino  acid  substitution  in  the
bevacizumab-binding site [7,16]. Therefore, the safety of anti-
rat VEGF antibody (ARVA) should be tested on rat retinas.
The retinal Müller glial cell (RMGC) is the principal glial
cell of the vertebrate retina. Retinal astrocytes are in contact
with the superficial vascular plexus via processes wrapped
around the vessels and ensheath all retinal neuronal somata
[4]. Our previous study showed expression of VEGF and
VEGF  receptors  (Flk-1,  Flt-1)  in  rat  RMGCs.  Partial
neuroprotective effects by exogenous VEGF on RMGCs were
also  observed  [5].  As  intravitreal  bevacizumab  has
increasingly been used to treat neovascular eye diseases, its
safety with RMGC or glial cells should be further studied.
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793This study is the first of its kind on the in vitro effects of
bevacizumab and anti-rat VEGF agent on RMGCs, as well as
on the in vivo effects of the intravitreal administration of the
two agents on glial cells.
METHODS
Animals:  Wistar  rats  (6  weeks  and  3–5  days  old)  were
purchased from Laboratory Animal Supply Center, Fourth
Military Medical University, China. The animals were kept
under standard laboratory conditions with a 12 h:12 h light-
dark cycle and were supplied with adequate food and water.
All  experiments  were  conducted  in  accordance  with  the
Animal Care and Use Committee and the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research.
Isolation, culture, and identification of rat retinal Müller glial
cells: Rat RMGCs were isolated according to the methods
described in a previous report [6]. Briefly, the enucleated eyes
of Wistar rats were placed in Dulbecco’s Modified Eagle
Medium (DMEM, Sigma-Aldrich, St. Louis, MO) containing
100 µg/ml streptomycin and 100 U/ml penicillin at room
temperature for 30 min. Twenty retinas were minced and the
suspension filtered through a 53 µm nylon mesh. Then, the
filtrate was collected and centrifuged at 500× g for 10 min and
the suspension were seeded onto clean two 75 cm2 tissue
culture flasks at 37 °C in a humidified 5% CO2 atmosphere.
The  medium  was  changed  and  non-attached  cells  were
discarded 24 h later. Retinal Müller glial cells were grown in
DMEM containing 200 ml/l heat-inactivated FBS, 2 mM L-
glutamine,  2  mM  sodium  pyruvate,  20  mM  4-(2-
hydroxyethyl)-1-piperazineethanesulfonic  acid  (HEPES),
10 mg/ml nonessential amino acids, 100 µg/ml streptomycin,
and  100  U/ml  penicillin.  The  above  medium  was  left
unchanged for 5 to 6 days and then was replaced every 3 to 4
days.  Cells  were  dissociated  from  the  flask  surface  with
2.5 mg/ml trypsin and 0.2 mg/ml EDTA (EDTA; TE) by
incubation at 37 °C. Cells of passages 2–4 were used for the
experiments. Müller glial cells were immunostained with anti-
vimentin  monoclonal  antibody  (V9  clone,  1:50  dilution,
Dako, Copenhagen, Denmark) and rabbit anti-glial fibrillary
acidic protein (GFAP) polyclonal antibody (1:50 dilution;
Dako). The second antibody was fluorescein isothiocyanate
(FITC) labeled immunoglobulin (1:200 dilution; Dako).
Cells treated with anti-vascular endothelial growth factor
agents:  Cells  were  cultured  to  70%  confluence,  and  cell
cultures were adapted into fresh culture medium 12 h before
the addition of anti-VEGF agents, which was serially diluted
in culture medium to appropriate concentrations just before
use. 0.1, 0.25, and 1 mg/ml bevacizumab (Genentech/Roche,
San Francisco, CA) and 0.1, 0.5, and 1 µg/ml of an anti-rat
VEGF monoclonal antibody (Clone 123704; ARVA; Leinco
Technologies, Inc. St. Louis, MO) were added to the RMGCs.
The  ARVA  could  block  rat  VEGF164—similar  to
bevacizumab’s specific neutralizing human VEGF165—but
not all isoforms. As controls, RMGCs were treated with fresh
culture  medium  with  and  without  1  mg  /ml  of  rat
immunoglobulin  G  (IgG),  a  nonspecific  antibody.  In  our
preliminary study, specificity of bevacizumab and ARVA to
rat RMGCs was tested with western blotting. Bevacizumab
could  not  bind  any  VEGF  isoforms  while  ARVA  could
specifically neutralize VEGF-164 expressed by rat RMGCs.
The amount of ARVA used in a previous report [7] was
pretested. After treated by ARVA with various concentrations
(0.1,  1,  and  10  µg/ml),  VEGF  expression  in  the  cultural
medium and the cytoplasm by RMGCs were measured using
an  enzyme  linked  immunosorbent  assay  and  an
immunofluorescence method. VEGF could not be detected
after treated by ARVA at 1 and 10 µg/ml concentrations, but
it could be detected after treated by 0.1 µg/ml of ARVA.
Furthermore, ARVA at a concentration of 0.5 µg/ml was
added in vitro study. Treated or untreated cells were collected
at 12, 24, 48, and 72 h for cell viability analysis. Cell viability
was  then  assessed  using  two  methods:  viable  cells  were
directly counted with trypan blue for the exclusion of dead
cells  and  mitochondrial  dehydrogenase  activity  was
quantified  using  a  methyl  thiazolyl  tetrazolium  (MTT)
colorimetric assay. Each measurement was performed at least
three times.
Intravitreal  injection:  The  rats  were  anesthetized
intraperitoneally  with  ketamine  (70  mg/kg,  Sigma)  and
xylazine (10 mg/kg, Sigma) and pupils were dilated with
Mydrin-P eye drops (Santen Pharmaceutical Co., Ltd., Osaka,
Japan).  Five  µl  of  bevacizumab  (3.75  mg/ml),  or  ARVA
(15 µg/ml), or rat IgG (1 mg/ml) was then injected into the
vitreous cavity of the right eye of each rat (n=6), as previously
described [17]. The intravitreal injection was performed with
a 30-gauge needle attached to a syringe through the sclera
1  mm  posterior  to  the  limbus,  guided  by  a  stereoscopic
microscope, with care taken to avoid lens and retinal injury.
Five µl of physiologic saline was injected intravitreally in the
left eye as control.
Electroretinogram:  Before  the  intravitreal  injection  and  7
days  after  injection,  the  Wistar  rats  were  dark-adapted
overnight,  anesthetized,  and  their  pupils  were  dilated.
Electroretinography  (ERG)  was  performed  using  the
GT-2000  system  (Guo-Te  medical  system,  Chongqing,
China). The scotopic flash responses were recorded from the
treated  and  control  eyes,  using  self-made  silver  chloride
corneal electrode rings. The reference and ground electrodes
were made of stainless steel surgical needles, and were placed
subcutaneously under each eye and in the tail. Light stimulus
was  presented  using  a  computer-controlled  miniature
Ganzfeld flash unit in a series of nine flashes with a maximum
intensity  of  2.0  cd•s•m−2,  and  responses  were  recorded.
Scotopic a-wave amplitudes were measured from baseline to
the corneal negative peak and b-wave amplitudes measured
from the corneal negative peak to the major corneal positive
peak after subtracting any contributions due to oscillatory
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794potentials. Three responses were then averaged for each flash
intensity.
Histologic examination: Following deep anesthesia, all rats
were perfused first with Ringer’s solution followed by 2%
paraformaldehyde in 0.1 M phosphate buffered saline (PBS)
at pH 7.4. The eyeballs were then removed and postfixed in
the same fixative for 4 h before being transferred into PBS
containing 200 mg/ml sucrose and kept overnight at 4 °C. Two
eyes in each group were dehydrated in a series of graded
alcohols,  and  embedded  in  paraffin.  Sections  of  5  µm
thickness were obtained using a microtome, and were stained
with hematoxylin-eosin. Slides were examined under a light
microscope. The other four eyes in each group were used for
immunohistologic analysis of GFAP. Frozen sagittal sections
of the eyes were cut at 20 µm thickness and mounted on
gelatin-coated slides. Mounted sections were washed for 20
min in PBS at pH 7.4. They were then incubated overnight
with the GFAP monoclonal antibody (1:50 dilution; Dako).
These  antibodies  were  diluted  with  PBS  containing  0.1%
Triton X-100. After incubation, sections were rinsed in PBS
for  15  min  and  reacted  using  the  Vectastain  ABC  Kit
(PK4002,  Vector  Laboratories,  Burlingame,  CA)  against
mouse  IgG  for  1  h.  They  were  then  treated  with  3,3′-
diaminobenzidine  tetrahydrochloride  as  the  peroxidase
substrate. After this, the sections were counterstained with 1%
methyl green, dehydrated, and mounted in Permount. Finally,
the fluorescent sections were observed and photographed with
a  confocal  laser  scanning  microscope  (CLSM  FV-300;
Olympus, Tokyo, Japan).
Statistical analysis: Statistical analysis was performed with
SPSS 13.0 (SPSS, Chicago, IL). The cell viability differences
among  the  various  treatment  groups  (treated  with
bevacizumab  at  various  concentrations)  and  rat  IgG  for
various periods were evaluated by ANOVA and the Student
t-test. The Mann–Whitney test and Wilcoxon matched-pair
signed  rank  test  were  used  to  evaluate  b-wave  amplitude
differences between control and treated eyes before and 7 days
after  injections.  A  p<0.05  was  considered  statistically
significant.
RESULTS
Effect of bevacizumab and ARVA on rat retinal Müller glial
cells viability in vitro: As shown in Figure 1, cultures of cells
exposed to bevacizumab at various concentrations and rat IgG
for various periods showed similar percentages of stained
cells with trypan blue. In contrast, RMGCs exposed to anti-
rat  VEGF  antibody  for  48  or  72  h  demonstrated  a  dose-
dependent increase in the percentage of trypan blue-stained
cells; the difference in the percentage of stained cells between
48 and 72 h was particularly remarkable after exposure to anti-
rat VEGF antibody at the concentrations of 0.5 and 1 µg/ml.
A  MTT  colorimetric  assay  was  used  to  quantify
mitochondrial dehydrogenase activity. As shown in Figure 2,
12 or 24 h after exposure, there was no significant difference
in optical density (an indicator of mitochondrial function)
among the groups. However, at 48 and 72 h after exposure to
anti-rat  VEGF  antibody,  the  cultures  of  RMGCs  had
significantly lower optical densities than the cells exposed to
fresh culture medium. The RMGCs exposed to bevacizumab
Figure 1. Trypan blue exclusion assay
showing the percentages of trypan blue-
positive  rat  retinal  Müller  glial  cells
(RMGCs)  after  exposure  to
bevacizumab (0.1, 0.25, and 1 mg/ml),
anti-rat  vascular  endothelial  growth
factor (VEGF) antibody (0.1, 0.5 and 1
μg/ml), 1 mg/ml of rat immunoglobulin
G (IgG), and control of fresh medium for
12, 24, 48, and 72 h . Data were shown
as mean±SD (n=5). The percentage of
stained  RMGCs  at  48  and  72  h
exposures to anti-rat VEGF antibody at
the concentrations of 0.5 and 1 μg/ml
increased remarkably. The percentage
of stained RMGCs was not affected after
exposure  to  bevacizumab,  IgG,  and
fresh control medium. The experiment
was performed at least three times with
similar results. *, p<0.01 significantly
differs  from  control.  #,  p<0.01
represents  significant  difference
between 48 and 72 h in 0.5 or 1 µg/ml
ARVA group.
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culture medium for various periods showed similar optical
densities.
Histologic  analysis:  Light  and  confocal  laser  scanning
microscopy was performed in all eyes. The histology of eyes
in both the treated and control group after intravitreal injection
was not distinguishable and no anatomic sign of toxicity was
observed.  There  was  no  obvious  upregulation  of  glial
fibrillary acidic protein (GFAP) in the RMGCs of any group
(Figure 3).
Effect of intravitreal injection of anti-vascular endothelial
growth factor agents on electroretinogram: The effects of
anti-VEGF agent intravitreal injections on retinal function
were assessed by ERG in this study as described previously
[18]. Electroretinogram analysis was based on measurements
of the b-wave amplitude from the trough of the a-wave to the
peak of the b-wave. The “Müller cell hypothesis” suggests that
the ERG b-wave comes from changes in RMGC membrane
potential,  which  arise  from  light-induced  fluctuations  of
extracellular  potassium  concentration  due  to  depolarizing
retinal neurons [19,20]. Scotopic ERG responses to flash light
were evaluated in dark-adapted rats before and 7 days after
intravitreal injection (Figure 4). The b-wave amplitude of the
bevacizumab group, anti-rat VEGF antibody group, rat IgG
group,  and  physiologic  saline  group  were  320.1±34.4,
335.3±19.7, 324.3±13.1, and 344.2±30.7 uv before injections,
respectively.  Seven  days  after  intravitreal  injections,  the
values  were  297.7±22.1,  321.6±35.7,  314.3±47.3,  and
329.3±36.4  uv,  respectively.  Intravitreal  injection  of  anti-
VEGF agents was not observed to decrease b-wave amplitude
significantly in any group.
DISCUSSION
In the past few years, dramatic new therapies with anti-VEGF
antibody  have  been  developed  as  treatment  options  for
patients having neovascular eye diseases, especially AMD
[2,3]. The safety and efficacy of anti-VEGF agents in the
treatment of these diseases has been evaluated and the results
indicate  that  the  intravitreal  administration  of  anti-VEGF
agents has limitations [21-23]. To date, many published data
showed that the bevacizumab agent was not harmful to retina
in vivo or to various retinal cells in vitro, while Spitzer et al.
reported that bevacizumab could exert a moderate growth
inhibition on pig choroidal endothelial cells and that high
doses of bevacizumab may be harmful to ARPE-19 cells, a
human  retinal  pigment  epithelial  cell  line,  in  vitro  [14].
Klettner et al. found that bevacizumab moderately impairs the
proliferation  of  porcine  RPE  cells  and  reduces  their
phagocytic function [24,25]. It has also been found that anti-
VEGF  agent  has  minimal  effects  on  the  permeability  or
selectivity of RPE tight junctions [26]. Retinal Müller glial
cells are a critical component in the retinal-blood barrier. With
anti-VEGF  agent  clinical  application  in  neovascular  eye
diseases, features of RMGC might be influenced. Currently,
there are no reports on the in vitro or in vivo toxic effects of
bevacizumab on RMGCs.
Retinal Müller glial cells span the entire thickness of the
inner retina, secret proangiogenic, and antiangiogenic factors,
such as VEGF, and may act as modulators of immune and
inflammatory  responses  under  pathological  conditions
[27-29]. Since intravitreal bevacizumab penetrates the retina
from  the  vitreal  side,  VEGF  in  RMGCs  were  inevitably
responded to anti-VEGF agents. The aim of this study was to
Figure 2. Methyl thiazolyl tetrazolium
(MTT) assay showing optical densities
of rat retinal Müller glial cells (RMGCs)
after exposure for 12, 24, 48, and 72 h
to bevacizumab (0.1, 0.25, and 1 mg/
ml), anti-rat vascular endothelial growth
factor (VEGF) antibody (0.1, 0.5 and 1
μg/ml), 1 mg/ml rat immunoglobulin G
(IgG), and fresh medium as a control.
Data  were  shown  as  the  mean±SD
(n=5). The optical densities of RMGCs
exposed  for  48  and  72  h  to  anti-rat
VEGF antibody at the concentrations of
0.5  μg/ml  and  1  μg/ml  decreased
remarkably.  The  optical  densities  of
RMGCs  were  not  affected  after
exposition  to  bevacizumab,  IgG,  and
fresh  control  medium.  Each  value
represents the mean of three replicates.
*, p<0.01 and +, p<0.05 differs from the
control. #, p<0.01 represents significant
difference  between  various  exposure
time in 0.5 or 1 µg/ml ARVA group.
Molecular Vision 2010; 16:793-799 <http://www.molvis.org/molvis/v16/a89> © 2010 Molecular Vision
796examine the effect of bevacizumab on RMGCs, which may
interfere with anti-VEGF agent treatment.
Retinal Müller glial cell gliosis is a response to virtually
every pathological alteration of the retina [30]. Gliotic RMGC
releases  factors  such  as  VEGF,  which  may  have  both
neuroprotective  and  detrimental  effects  as  VEGF  may
exacerbate neovascular disease progression [31]. The most
sensitive non-specific response to retinal diseases and injuries,
which can be used as a universal early cellular marker for
retinal  injury,  is  the  upregulation  of  glial  fibrillary  acidic
protein (GFAP) [32,33].
In the present study, no GFAP upregulation of RMGCs
was  observed  in  the  retina  in  vivo  after  intravitreal
bevacizumab injection at a high concentration of 3.75 mg/ml.
No evidence for retinal toxicity resulting from the intravitreal
bevacizumab  injection  in  rat  model  were  found  based  on
electrophysiology  in  this  study.  In  addition,  the  effect  of
bevacizumab on cultured RMGCs was also examined. No
toxic or anti-proliferative effect on RMGCs was observed
with 0.1 to 1 mg/ml bevacizumab.
However, since bevacizumab is human-specific and does
not react with rat VEGF, anti-rat VEGF antibody was further
examined in vivo and in vitro on rat RMGCs with similar
assays as used by Iriyama et al. [7].
When 0.5 and 1 µg/ml anti-rat VEGF antibody was used,
an increased percentage of cell death and anti-proliferation
effect on RMGCs were observed after 48 and 72 h incubation.
Previous  studies  found  that  VEGF  exerts  neuroprotective
effects on various cultured neurons and glial cells [17] and
RMGCs  might  lose  these  neuroprotective  effects  after
RMGCs  secreted  VEGF  consumed  by  anti-rat  VEGF
antibody. It has been reported that VEGF, one of the hypoxia
inducible  factor-1  target  gene  products,  shows  protective
effects against neuron apoptosis induced by brain ischemia
[34].  Hypoxia  inducible  factor-1,  possibly  implicated  in
pyruvate kinase induction, has regulating effects on glial cells
death in hypoxic environment [35]. Therefore, in in vitro
study, ARVA blocked VEGF and might induce apoptosis of
RMGCs.  However,  intravitreal  injected  anti-rat  VEGF
antibody neither increased the expression of GFAP in the
retina nor decreased the amplitude of b-wave in rat ERG,
suggesting  that  VEGF  antibody  is  not  associated  with
significant retinal toxicity. Although the expression of GFAP
in RMGCs was not been observed after intravitreal injection,
Figure 3. The histologic sections of the retina with hematoxylin and eosin (HE) staining 7 days after intravitreal injection of 5 µl of 3.75 mg/
ml bevacizumab (A), 15 µg/ml anti-rat vascular endothelial growth factor (VEGF) antibody (B), 1 mg/ml rat immunoglobulin G (IgG; C),
and physiologic saline (D). E–H are the fluorescence images of glial fibrillary acidic protein (GFAP)-immunolabeled sections 7 days after
intravitreal injection of bevacizumab (E), anti-rat VEGF antibody (F), rat IgG (G), and physiologic saline (H). The scale bar represents 20
µm.
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797the direct effects of anti-VEGF agent on RMGCs cannot be
excluded.
In summary, bevacizumab and anti-rat VEGF agent did
not appear to be toxic to the retina in rats. This study supports
the  safety  of  intravitreal  anti-VEGF  agent  treatments  of
choroidal  neovascularization  and  retinal  neovascular
diseases. Further studies are still required to evaluate the long-
term safety of the drugs.
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